Can Aptar Pharma help solve the bioequivalence challenge in next-generation inhalers?
Greener inhalers need more than lower-carbon chemistry. Aptar Pharma’s FDA-backed work tests the science regulators may need.
What SPONTAN reveals about Aptar’s nasal drug delivery platform and the race for rapid acting erectile dysfunction treatments
Aptar’s nasal drug delivery system enters Phase II trial for LTR Pharma’s SPONTAN erectile dysfunction therapy. Discover what this means for intranasal medicines.
Aptar Pharma and COVIRIX Medical partner to develop inhaled broad-spectrum antiviral treatment
Aptar Pharma and COVIRIX Medical announce a DPI feasibility collaboration for inhaled broad-spectrum antivirals. Read the analysis.